Methods for treating, diagnosing and prognosing a haematological malignancy

Abstract

The invention relates to a serotonin receptor (5-HTR) inhibitor selected from the group consisting of a type 1 5-HTR inhibitor and a type 2 5-HTR inhibitor for use in the prevention and/or treatment of a haematological malignancy. Additionally, the invention relates to in vitro methods for the identification or isolation of a malignant cell from a haematological malignancy or for diagnosing a haematological malignancy based on detecting the expression of type 1 5-HTR and/or type 2 5-HTR. Furthermore, the invention relates to in vitro methods for determining the prognosis, for monitoring the effect of a therapy or for designing a customized therapy in a subject suffering from a haematological malignancy based on determining the levels of type 1 5-HTR and or type 2 5-HTR.

1 - 34 . (canceled) 
     
     
         35 . A method for designing a customized therapy for a subject comprising:
 (a) determining the protein expression level of a type 1 5-HTR and/or type 2 5-HTR biomarker in cells of a sample from a subject with acute myeloid leukaemia (AML), and   (b) comparing said biomarker protein expression level with a biomarker protein expression reference value   
       wherein
 (i) a decrease of the biomarker protein expression level of type 1 5-HTR and/or type 2 5-HTR biomarker with respect to the biomarker protein expression reference value is indicative of good prognosis, and 
 (ii) an increase of the biomarker protein expression level of type 1 5-HTR and/or type 2 5-HTR biomarker with respect to the biomarker protein expression reference value is indicative of poor prognosis.